|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Diarrhea | |||||
| 2 | More general conditions related to this trial | ||||
| Signs and Symptoms | |||||
| Signs and Symptoms, Digestive | |||||
| 3 | Interventions listed in this trial | ||||
| rifaximin | |||||
| 4 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Gastrointestinal Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| DuPont, Hurbert L., MD | |||||
| Salix Pharmaceuticals | |||||
| The University of Texas Health Science Center, Houston | |||||